Meeting
2012 Genitourinary Cancers Symposium
Prognostic factors for survival in the phase III TROPIC trial.
Authors
A. Oliver Sartor
Tulane Cancer Center, New Orleans, LA
A. Oliver Sartor , Stéphane Oudard , Mustafa Ozguroglu , Steinbjorn Hansen , Jean-Pascal H. Machiels , Ivo Kocak , Gwenaelle Gravis , Istvan Bodrogi , Mary J. MacKenzie , Francisco Jorquera Orlandi , Liji Shen , Johann Sebastian De Bono
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT00417079
Citation
J Clin Oncol 30, 2012 (suppl 5; abstr 102^)
Abstract #
102^
Poster Bd #
B7
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Cabozantinib for metastatic castration-resistant prostate cancer (mCRPC) following docetaxel: Combined analysis of two phase III trials.
First Author: Gregory Russell Pond
Poster
2011 Genitourinary Cancers Symposium
Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Estimating mean overall survival (OS) for health economic analyses from a phase III trial (TROPIC).
First Author: Stephane Oudard
Poster
2013 ASCO Annual Meeting
PROSELICA study update: Comparison of two doses of cabazitaxel (Cbz) plus prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen.
First Author: Mario A. Eisenberger
Poster
2012 ASCO Annual Meeting
Comparison of two doses of cabazitaxel plus prednisone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen.
First Author: Mario A. Eisenberger